Products
Platform
Research
Market
Learn
Compare WhiteOak Capital Pharma and Healthcare Fund vs ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Fund Details
Risk | Very High | Very High |
Rating | - | 5.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 2.38 | 1.87 |
NAV | ₹13.99 | ₹39.90 |
Fund Started | 16 Jan 2024 | 25 Jun 2018 |
Fund Size | ₹480.08 Cr | ₹6437.36 Cr |
Exit Load | Exit load of 1%, if redeemed within 1 months. | Exit load of 1% if redeemed within 15 days. |
Risk
Very High
Very High
Rating
-
5.0
Min SIP Amount
₹100
₹100
Expense Ratio
2.38
1.87
NAV
₹13.99
₹39.90
Fund Started
16 Jan 2024
25 Jun 2018
Fund Size
₹480.08 Cr
₹6437.36 Cr
Exit Load
Exit load of 1%, if redeemed within 1 months.
Exit load of 1% if redeemed within 15 days.
Returns
1 Year | 7.94% | 5.80% |
3 Year | - | 26.90% |
5 Year | - | 19.51% |
1 Year
7.94%
5.80%
3 Year
-
26.90%
5 Year
-
19.51%
Holding Analysis
Equity | 99.24% | 97.10% |
Cash | -8.42% | 2.90% |
Equity
99.24%
97.10%
Cash
-8.42%
2.90%
Top Holdings
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 7.82% |
Divi's Laboratories Ltd. | 6.87% |
JB Chemicals & Pharmaceuticals Ltd. | 6.48% |
Fortis Healthcare Ltd. | 6.32% |
Laurus Labs Ltd. | 4.68% |
Cipla Ltd. | 4.20% |
Neuland Laboratories Ltd. | 3.82% |
Lupin Ltd. | 3.73% |
Sun Pharmaceutical Industries Ltd. | 3.07% |
Sai Life Sciences Ltd. | 2.94% |
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 11.88% |
Dr. Reddy's Laboratories Ltd. | 9.42% |
Divi's Laboratories Ltd. | 8.50% |
Aurobindo Pharma Ltd. | 7.62% |
Cipla Ltd. | 6.61% |
Lupin Ltd. | 5.40% |
Alkem Laboratories Ltd. | 3.98% |
Biocon Ltd. | 3.28% |
Mankind Pharma Ltd. | 2.79% |
Zydus Lifesciences Ltd. | 2.67% |
Fund Manager
Name | Trupti Agrawal | Dharmesh Kakkad |
Start Date | 15 May 2024 | 23 Feb 2021 |
Name
Trupti Agrawal
Dharmesh Kakkad
Start Date
15 May 2024
23 Feb 2021
About Fund
Description | The Scheme seeks to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 16 Jan 2024 | 25 Jun 2018 |
Description
The Scheme seeks to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies.
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
Launch Date
16 Jan 2024
25 Jun 2018